Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant
Por um escritor misterioso
Descrição
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology - ScienceDirect
Cancers, Free Full-Text
ASCO GU 2023: EVOLUTION: Phase II Study of Radionuclide 177Lu-PSMA-617 Therapy Versus 177Lu-PSMA-617 in Combination with Ipilimumab and Nivolumab for Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC; ANZUP 2001)
Management of Castration-Resistant Prostate Cancer
Immunotherapy in Prostate Cancer: Recent Advances and Future Directions - European Medical Journal
Current therapy and drug resistance in metastatic castration-resistant prostate cancer - ScienceDirect
Cancers, Free Full-Text
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors - European Urology
Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer - European Urology Focus
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
